上皮性卵巢癌症患者血清和肿瘤组织中ACRBP表达与一线化疗效果和预后的关系  

Correlation of ACRBP expression in serum and tumor tissues with first-line chemotherapy and prognosis in patients with epithelial ovarian cancer

作　　者：赵建红 岑红兵 杨志勇 ZHAO Jianhong;CEN Hongbing;YANG Zhiyong(Department of Pathology,Huanggang Central Hospital Affiliated to Yangtze University,Huanggang,Hubei 438000,China;Department of Oncology,Huanggang Central Hospital Affiliated to Yangtze University,Huanggang,Hubei 438000,China)

机构地区：[1]长江大学附属黄冈市中心医院病理科,湖北黄冈438000 [2]长江大学附属黄冈市中心医院肿瘤科,湖北黄冈438000

出　　处：《国际检验医学杂志》2024年第10期1153-1158,共6页International Journal of Laboratory Medicine

基　　金：湖北省卫生健康委员会科研项目(WJ2021M070)。

摘　　要：目的探讨上皮性卵巢癌(EOC)患者血清和肿瘤组织中顶体素结合蛋白(ACRBP)表达与一线化疗效果和预后的关系。方法使用从基因表达谱互动分析数据库中获得的数据分析卵巢癌(OC)中ACRBP mRNA的表达和预后作用。收集2019年10月至2021年12月在该院接受手术的95例EOC患者的组织标本和血清样本。另外,收集30例卵巢良性肿瘤物组织样本作为良性肿瘤对照组,收集30例健康志愿者血清样本作为健康对照组。采用免疫组织化学染色法检测组织ACRBP表达。一线化疗完成后,使用实体肿瘤疗效评价标准1.1版评估化疗效果分为敏感组和耐药组。敏感组包括完全缓解(CR)者和部分缓解(PR)者,耐药组包括疾病稳定(SD)者和疾病进展(PD)者。结果公共数据库中,OC患者组织ACRBP mRNA表达明显升高(P<0.05),且其高表达与总生存期(OS)较差有关。临床样本中,ACRBP主要在EOC肿瘤细胞的细胞质中表达,而在良性对照组卵巢组织中均未检测到ACRBP。一线化疗耐药组患者组织ACRBP表达显著高于敏感组,差异有统计学意义(P<0.001)。组织ACRBP表达预测一线化疗耐药的受试者工作特征(ROC)曲线下面积(AUC)为0.830(95%CI:0.743~0.916),此时的截断值为8.65分,灵敏度和特异度分别为80.0%和77.1%。ACRBP高表达是EOC患者OS和PFS预后的独立危险因素(P<0.05)。根据组织ACRBP表达中位值,将EOC患者分为ACRBP低表达组(<8.27分)和高表达组(≥8.27分)。组织ACRBP高表达组患者OS和无进展生存期(PFS)明显更短(P<0.05)。结论EOC患者组织ACRBP高表达与一线化疗耐药和预后不良密切相关。ACRBP有希望成为一线化疗效果和预后预测的新型生物标志物。Objective To detect the expression of acrosin binding protein(ACRBP)in serum and tumor tissue of patients with epithelial ovarian cancer(EOC),and to investigate the relationship between the expression of acrosin binding protein(ACRBP)in serum and tumor tissue of patients with epithelial ovarian cancer(EOC)and first-line chemotherapy effect and prognosis.Methods The expression and prognostic effects of ACRBP mRNA in OC were analyzed using data obtained from Gene Expression Profiling Interactive Analysis Database.Then,tissue specimens and serum samples were collected from 95 patients with EOC who underwent surgery at the hospital between October 2019 and December 2021.In addition,30 samples of ovarian benign tumor tissue were selected as the benign tumor control group and 30 serum samples from healthy volunteers were selected as the normal control group.The expression of ACRBP was detected by immunohistochemical staining.After first-line chemotherapy was completed,solid tumor efficacy evaluation criteria version 1.1 was used to evaluate chemotherapy effects,and the patients were divided into sensitive group and drug-resistant group.The sensitive group included complete response(CR)and partial response(PR)patients,and the drug-resistant group included stable disease(SD)and progressive disease(PD)patients.Results In the public database,ACRBP mRNA expression was significantly increased in OC patients(P<0.05),and its high expression was associated with poor overall survival(OS).In clinical samples,ACRBP was mainly expressed in the cytoplasm of EOC tumor cells,while no ACRBP was detected in the ovarian tissues of benign tumor control group.The expression of ACRBP in first-line chemotherapy resistant group was significantly higher than that in sensitive group,and the difference was statistically significant(P<0.001).The area under receiver operating characteristic(ROC)curve of ACRBP expression for predicting first-line chemotherapy resistance was 0.830(95%CI:0.743-0.916),the cut off value was 8.65 points,and the sensitiv

关 键 词：上皮性卵巢癌 顶体素结合蛋白 一线化疗效果 预后 

分 类 号：R737.31[医药卫生—肿瘤]